Display options
Cite
Functional brain imaging: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(22):1-79
(2006). Functional brain imaging: an evidence-based analysis. Ontario health technology assessment series, 6(22), 1-79.
"Functional brain imaging: an evidence-based analysis." Ontario health technology assessment series vol. 6,22 (2006): 1-79.
Functional brain imaging: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(22):1-79. Epub 2006 Dec 01. PMID: 23074493; PMCID: PMC3379170.
Copy Download .nbib Format: NLM
Share it on

Ont Health Technol Assess Ser. 2006;6(22):1-79. Epub 2006 Dec 01.

Functional brain imaging: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]

PMID: 23074493 PMCID: PMC3379170

Abstract

OBJECTIVE: The objective of this analysis is to review a spectrum of functional brain imaging technologies to identify whether there are any imaging modalities that are more effective than others for various brain pathology conditions. This evidence-based analysis reviews magnetoencephalography (MEG), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI) for the diagnosis or surgical management of the following conditions: Alzheimer's disease (AD), brain tumours, epilepsy, multiple sclerosis (MS), and Parkinson's disease (PD).

CLINICAL NEED: TARGET POPULATION AND CONDITION Alzheimer's disease is a progressive, degenerative, neurologic condition characterized by cognitive impairment and memory loss. The Canadian Study on Health and Aging estimated that there will be 97,000 incident cases (about 60,000 women) of dementia (including AD) in Canada in 2006. In Ontario, there will be an estimated 950 new cases and 580 deaths due to brain cancer in 2006. Treatments for brain tumours include surgery and radiation therapy. However, one of the limitations of radiation therapy is that it damages tissue though necrosis and scarring. Computed tomography (CT) and magnetic resonance imaging (MRI) may not distinguish between radiation effects and resistant tissue, creating a potential role for functional brain imaging. Epilepsy is a chronic disorder that provokes repetitive seizures. In Ontario, the rate of epilepsy is estimated to be 5 cases per 1,000 people. Most people with epilepsy are effectively managed with drug therapy; but about 50% do not respond to drug therapy. Surgical resection of the seizure foci may be considered in these patients, and functional brain imaging may play a role in localizing the seizure foci. Multiple sclerosis is a progressive, inflammatory, demyelinating disease of the central nervous system (CNS). The cause of MS is unknown; however, it is thought to be due to a combination of etiologies, including genetic and environmental components. The prevalence of MS in Canada is 240 cases per 100,000 people. Parkinson's disease is the most prevalent movement disorder; it affects an estimated 100,000 Canadians. Currently, the standard for measuring disease progression is through the use of scales, which are subjective measures of disease progression. Functional brain imaging may provide an objective measure of disease progression, differentiation between parkinsonian syndromes, and response to therapy.

THE TECHNOLOGY BEING REVIEWED: FUNCTIONAL BRAIN IMAGING: Functional brain imaging technologies measure blood flow and metabolism. The results of these tests are often used in conjunction with structural imaging (e.g., MRI or CT). Positron emission tomography and MRS identify abnormalities in brain tissues. The former measures abnormalities through uptake of radiotracers in the brain, while the latter measures chemical shifts in metabolite ratios to identify abnormalities. The potential role of functional MRI (fMRI) is to identify the areas of the brain responsible for language, sensory and motor function (sensorimotor cortex), rather than identifying abnormalities in tissues. Magnetoencephalography measures magnetic fields of the electric currents in the brain, identifying aberrant activity. Magnetoencephalography may have the potential to localize seizure foci and to identify the sensorimotor cortex, visual cortex and auditory cortex. In terms of regulatory status, MEG and PET are licensed by Health Canada. Both MRS and fMRI use a MRI platform; thus, they do not have a separate licence from Health Canada. The radiotracers used in PET scanning are not licensed by Health Canada for general use but can be used through a Clinical Trials Application.

REVIEW STRATEGY: The literature published up to September 2006 was searched in the following databases: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Cochrane Database of Systematic Reviews, CENTRAL, and International Network of Agencies for Health Technology Assessment (INAHTA). The database search was supplemented with a search of relevant Web sites and a review of the bibliographies of selected papers. General inclusion criteria were applied to all conditions. Those criteria included the following: Full reports of systematic reviews, randomized controlled trials (RCTs), cohort-control studies, prospective cohort studies (PCS'), and retrospective studies.Sample sizes of at least 20 patients (≥ 10 with condition being reviewed).English-language studies.Human studies.Any age.STUDYING AT LEAST ONE OF THE FOLLOWING: fMRI, PET, MRS, or MEG.Functional brain imaging modality must be compared with a clearly defined reference standard.MUST REPORT AT LEAST ONE OF THE FOLLOWING OUTCOMES: sensitivity, specificity, accuracy, positive predictive value (PPV), receiver operating characteristic curve, outcome measuring impact on diagnostic testing, treatment, patient health, or cost.

SUMMARY OF FINDINGS: There is evidence to indicate that PET can accurately diagnose AD; however, at this time, there is no evidence to suggest that a diagnosis of AD with PET alters the clinical outcomes of patients. The addition of MRS or O-(2-(18)F-Fluoroethyl)-L-Tyrosine (FET)-PET to gadolinium (Gd)-enhanced MRI for distinguishing malignant from benign tumours during primary diagnosis may provide a higher specificity than Gd-enhanced MRI alone. The clinical utility of additional imaging in patients to distinguish malignant from benign tumours is unclear, because patients with a suspected brain tumour will likely undergo a biopsy despite additional imaging results. The addition of MRS, FET-PET, or MRI T2 to Gd-enhanced MRI for the differentiation of recurrence from radiation necrosis may provide a higher specificity than Gd-enhanced MRI alone. The clinical utility of additional imaging in patients with a suspected recurrence is in the monitoring of patients. Based on the evidence available, it is unclear if one of the imaging modalities (MRS, FET-PET, or MRI T2) offers significantly improved specificity over another. There may be a role for fMRI in the identification of surgical candidates for tumour resection; however, this requires further research. Based on the studies available, it is unclear if MEG has similar accuracy in localizing seizure foci to intracranial electroencephalogram (ICEEG). More high-quality research is needed to establish whether there is a difference in accuracy between MEG and ICEEG. The results of the studies comparing PET to noninvasive electroencephalogram (EEG) did not demonstrate that PET was more accurate at localizing seizure foci; however, there may be some specific conditions, such as tuberous sclerosis, where PET may be more accurate than noninvasive EEG. There may be some clinical utility for MEG or fMRI in presurgical functional mapping; however, this needs further investigation involving comparisons with other modalities. The clinical utility of MRS has yet to be established for patients with epilepsy. Positron emission tomography has high sensitivity and specificity in the diagnosis of PD and the differential diagnosis of parkinsonian syndromes; however, it is unclear at this time if the addition of PET in the diagnosis of these conditions contributes to the treatment and clinical outcomes of patients. There is limited clinical utility of functional brain imaging in the management of patients with MS at this time. Diagnosis of MS is established through clinical history, evoked potentials, and MRI. Magnetic resonance imaging can identify the multifocal white lesions and other structural characteristics of MS.

References

  1. Brain. 2003 Nov;126(Pt 11):2396-405 - PubMed
  2. Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9 - PubMed
  3. Radiology. 2004 Apr;231(1):73-80 - PubMed
  4. AJNR Am J Neuroradiol. 1999 Sep;20(8):1511-9 - PubMed
  5. Radiology. 2005 Jul;236(1):247-53 - PubMed
  6. Acta Radiol. 2006 Feb;47(1):85-90 - PubMed
  7. Neurology. 2000 Jul 12;55(1):66-73 - PubMed
  8. Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 - PubMed
  9. Neurosurg Focus. 2003 Jul 15;15(1):E7 - PubMed
  10. Radiology. 2006 Oct;241(1):213-22 - PubMed
  11. Acta Radiol. 2005 Oct;46(6):599-609 - PubMed
  12. Ann Neurol. 2006 Aug;60(2):270 - PubMed
  13. Epilepsia. 2004 Jun;45(6):641-9 - PubMed
  14. Epilepsia. 2005 May;46(5):688-95 - PubMed
  15. Clin Neurophysiol. 2004 Sep;115(9):2066-76 - PubMed
  16. J Neurosurg. 2004 May;100(5):867-76 - PubMed
  17. Epilepsia. 2001 Feb;42(2):282-6 - PubMed
  18. Brain. 2005 May;128(Pt 5):1188-98 - PubMed
  19. Lancet Neurol. 2004 May;3(5):284-90 - PubMed
  20. N Engl J Med. 1996 Mar 7;334(10):647-52 - PubMed
  21. Epilepsia. 2006 Aug;47(8):1308-19 - PubMed
  22. Med Decis Making. 1991 Apr-Jun;11(2):88-94 - PubMed
  23. Clin Auton Res. 2004 Apr;14(2):84-91 - PubMed
  24. Eur J Neurol. 2001 Nov;8(6):573-7 - PubMed
  25. J Neurosurg. 1999 Nov;91(5):787-96 - PubMed
  26. Radiology. 2006 Sep;240(3):793-802 - PubMed
  27. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):103-9 - PubMed
  28. Neurosurg Rev. 2004 Jan;27(1):1-18; discussion 19-21 - PubMed
  29. Electroencephalogr Clin Neurophysiol Suppl. 1996;46:209-13 - PubMed
  30. Hum Brain Mapp. 2001 Mar;12(3):180-92 - PubMed
  31. Neurology. 2004 Mar 23;62(6):943-8 - PubMed
  32. J Comput Assist Tomogr. 2000 Nov-Dec;24(6):927-34 - PubMed
  33. Lancet Neurol. 2006 Jan;5(1):75-86 - PubMed
  34. Ann Neurol. 2006 May;59(5):835-42 - PubMed
  35. Ann Neurol. 1999 Oct;46(4):627-33 - PubMed
  36. J Int Med Res. 2006 Jul-Aug;34(4):339-47 - PubMed
  37. AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 - PubMed
  38. J Nucl Med. 2005 Oct;46(10):1625-32 - PubMed
  39. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1311-6 - PubMed
  40. CMAJ. 1994 Mar 15;150(6):899-913 - PubMed
  41. Epilepsia. 1995 Mar;36(3):230-5 - PubMed
  42. J Clin Neurophysiol. 2005 Aug;22(4):231-7 - PubMed
  43. Epilepsia. 2004 Dec;45(12):1623-9 - PubMed
  44. Neurology. 2003 Sep 9;61(5):699-701 - PubMed
  45. Mult Scler. 2005 Oct;11(5):516-9 - PubMed
  46. Clin Cancer Res. 2004 Nov 1;10(21):7163-70 - PubMed
  47. AJR Am J Roentgenol. 2005 Dec;185(6):1471-6 - PubMed
  48. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 - PubMed
  49. Neurology. 1996 Apr;46(4):978-84 - PubMed
  50. Neuroimage. 2006 Oct 1;32(4):1793-803 - PubMed
  51. J Child Neurol. 2005 Nov;20(11):885-92 - PubMed
  52. Magn Reson Imaging. 2006 Nov;24(9):1131-42 - PubMed
  53. Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):200-9 - PubMed
  54. Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1128-35 - PubMed
  55. J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1152-7 - PubMed
  56. Ann Neurol. 2005 Oct;58(4):525-32 - PubMed
  57. Neurosurgery. 2004 May;54(5):1111-7; discussion 1117-9 - PubMed
  58. J Nucl Med. 2005 Dec;46(12):1948-58 - PubMed
  59. Am J Alzheimers Dis Other Demen. 2006 Mar-Apr;21(2):73-8 - PubMed
  60. Ann Neurol. 2006 Aug;60(2):271 - PubMed
  61. Brain Tumor Pathol. 2000;17(2):57-64 - PubMed
  62. J Neurosurg. 2002 Oct;97(4):865-73 - PubMed
  63. Value Health. 2003 Sep-Oct;6(5):542-50 - PubMed
  64. Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9 - PubMed
  65. BMJ. 2006 Apr 15;332(7546):875-84 - PubMed
  66. Dement Geriatr Cogn Disord. 2005;20(2-3):63-70 - PubMed
  67. Neurology. 1999 Sep 22;53(5):938-45 - PubMed
  68. Neurology. 2003 Jun 10;60(11):1788-92 - PubMed
  69. Clin Neurol Neurosurg. 2004 Dec;107(1):20-6 - PubMed
  70. Epilepsia. 2006 Mar;47(3):574-9 - PubMed
  71. Epilepsia. 1998 Dec;39(12):1302-8 - PubMed
  72. BMJ. 2004 Jun 19;328(7454):1490 - PubMed
  73. J Child Neurol. 2001 Feb;16(2):124-30 - PubMed
  74. J Neurosurg. 2005 Feb;102(2):318-27 - PubMed
  75. J Neurosurg. 1999 Jul;91(1):73-9 - PubMed
  76. Neurology. 2001 Sep 11;57(5):871-8 - PubMed
  77. J Neural Transm Suppl. 2006;(70):241-8 - PubMed
  78. J Nucl Med. 2006 Jun;47(6):904-11 - PubMed
  79. J Am Geriatr Soc. 2003 Feb;51(2):258-64 - PubMed
  80. AJNR Am J Neuroradiol. 2006 Aug;27(7):1404-11 - PubMed
  81. Q J Nucl Med Mol Imaging. 2006 Mar;50(1):88-93 - PubMed
  82. Neuroimage. 1999 Dec;10(6):738-48 - PubMed
  83. Neuroimage. 2005 Jul 1;26(3):912-21 - PubMed
  84. J Image Guid Surg. 1995;1(6):339-47 - PubMed
  85. Epilepsia. 2005 Jan;46(1):59-68 - PubMed
  86. Health Technol Assess. 2006 Feb;10(4):1-250, iii-iv - PubMed
  87. Neurosurgery. 2004 Oct;55(4):904-14; discusssion 914-5 - PubMed
  88. Epilepsia. 2006 Feb;47(2):355-64 - PubMed
  89. Epilepsia. 1997 Apr;38(4):452-60 - PubMed
  90. Brain. 2005 Mar;128(Pt 3):678-87 - PubMed
  91. Neurology. 2001 Oct 23;57(8):1497-9 - PubMed
  92. Neuroradiology. 2005 Nov;47(11):826-34 - PubMed
  93. Neurosurgery. 2006 Sep;59(3):493-510; discussion 510-1 - PubMed
  94. Epilepsia. 1999 Jul;40(7):931-41 - PubMed
  95. Int J Technol Assess Health Care. 2006 Spring;22(2):143-8 - PubMed

Publication Types